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Abstract 1 
Background: Candidemia is a serious hazard to hospitalized patients, but European 2 
epidemiological data is restricted to national studies focusing on Northern Europe, 3 
population-based surveillance programs or studies conducted in distinct local areas. 4 
Objectives: To provide current data on the overall burden and epidemiological development 5 
of candidemia in Europe. 6 
Data sources: Web of Knowledge™ search from January 2000 and February 2019. 7 
Study eligibility criteria: Appropriate data on total cases, study duration, incidence, species 8 
distribution and/or mortality rates. 9 
Interventions: Meta-analysis to pool individual studies. Heterogeneity was examined by I2 10 
statistic. Calculation of pooled incidence and mortality rates, subgroup analysis by 11 
geographical origin, study period and scenarios. Extrapolation of daily candidaemia incidence 12 
and mortality rates in Europe. 13 
Methods: Systematic review and meta-analysis to determine incidence and mortality of 14 
candidemia in the UN European region. Complete datasets were categorized into population-15 
based and hospital-based epidemiological studies and were analyzed separately. Subgroup 16 
analyses were performed for geographic distributions and time-dependent developments. 17 
Results: In population-based studies, 43,799 cases of candidemia were diagnosed in 18 
1,885,271,885 person-years, revealing an overall pooled incidence rate of 3.88/100,000. The 19 
highest pooled incidence rate was observed in intensive care units (5.5/1,000 admissions, Day 20 
30 mortality rate 37%), followed by tertiary care centers (0.96/1,000 admissions, pooled day 21 
30 mortality rate 38%) and the mixed group of teaching and general hospitals (0.52/1,000 22 
admissions, pooled Day 30 mortality rate 37%). European incidence of candidemia was 23 
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extrapolated to approximately 79 cases per day, of which an estimated 29 patients might have 24 
fatal outcome at day 30. 25 
Conclusion: Pooled incidence rates, species distribution and outcome of candidemia differ 26 
considerably between clinical groups, European regions and over time. We observed an 27 
increasing overall pooled incidence rate of candidemia and a higher proportion of Candida 28 
spp. other than C. albicans in the current decade in population-based data.  29 
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Introduction 30 
Over the last decades, the management of candidaemia has continuously evolved with respect 31 
to advanced treatment algorithms and availability of new antifungal drugs.1,2 However, 32 
candidaemia remains a serious hazard to hospitalized patients and increases health care 33 
costs.3-5 Most guidelines define candidaemia as isolation of Candida spp. from at least one 34 
peripheral or central line blood culture, a diagnostic method with a 50–75% overall 35 
sensitivity.2,6-8 Candida spp. are the fourth most common cause of nosocomial bloodstream 36 
infections (BSI) in the United States of America (9%) with a mean of 22 days from admission 37 
to infection.9 BSI surveillance showed 6% of BSI being caused by Candida spp. in Estonia,10 38 
in contrast to only 1% in Spain.11 The majority of European data on candidaemia originates 39 
from single institutions,12-15 hospital networks,16-19 and national surveillance programs.20-23 40 
Candida albicans remains the most prevalent species.9,20,24-26 A shift towards Candida spp. 41 
other than C. albicans (non-albicans Candida, NAC), in particular C. glabrata complex, has 42 
been observed globally,25-27 and Candida auris sets a worrisome trend with globally reported 43 
outbreaks.28,29 44 
Nationwide population-based surveillance programs on morbidity and mortality of 45 
candidaemia were executed in Northern Europe (Denmark, Iceland, Sweden),20,21,25 and in the 46 
United States.30-33 In Western Europe, most studies are limited to smaller geographical 47 
regions.34-37 In addition to population-based surveillance programs, hospital and laboratory-48 
based studies allow characterization of epidemiology in teaching hospitals (TH), general 49 
hospitals (GH), and intensive care units (ICU). Published epidemiological data is highly 50 
divergent and heterogeneous. Standardized work-up and reporting strategies currently do not 51 
exist. Epidemiological efforts are needed to improve the understanding of the impact of 52 
candidaemia on patient outcomes in Europe and are important for tracking trends across 53 
geography, time and hospital settings. The contemporary epidemiology of candidaemia in the 54 
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era of modern antifungal therapy warrants more study. Therefore, we conducted a systematic 55 
literature review and meta-analysis focusing on incidence and mortality in different periods, 56 
regions and clinical groups to synthesize the results available from European assessments. 57 
 58 
Methods 59 
Search strategy and selection criteria 60 
We conducted a Web of Knowledge™ search for English language articles on candidemia 61 
and Candida epidemiology with predefined search algorithms (Table S4 and S5). The latest 62 
search was performed in 28th of February 2019. Time span was defined as publication date 63 
between January 1, 2000 and February 28, 2019. Given progressive changes in clinical and 64 
microbiological diagnostic methods, older studies were not included for lack of relevance and 65 
comparability. Concerning mortality analysis, we differentiated between crude mortality and 66 
Day 30 mortality rates. Additional information on the methodology of data selection, 67 
extraction and calculation is part of the Supplement (Data extraction and selection, and 68 
formulary). 69 
 70 
Meta-analysis 71 
A meta-analysis was conducted to pool individual studies by using a random effect model of 72 
DerSimonian and Laird.38 Heterogeneity was examined by using the I2 statistic.39 We 73 
calculated the pooled incidence and mortality rates and performed subgroup analysis by 74 
geographical origin, study period and scenarios (laboratory vs. hospital-based data, 75 
prospective vs. retrospective) to compare heterogeneity. We further conducted a random 76 
meta-regression model to determine the influence of the different study factors on pooled 77 
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estimate effects.40 Significance was set at the α level of 0·05. Statistical analysis used Stata 78 
version 14.0. 79 
 80 
Stratification 81 
We grouped studies according to their median time point during study period and 82 
differentiated according to three decades, 1990-2000, 2001-2010 and 2011-Now. Studies were 83 
allocated to European sub-regions according to United Nations geoscheme for Europe defined 84 
by the United Nations Statistics Division.41 It divides the European continent into Northern, 85 
Eastern, Southern and Western Europe. C. albicans and NAC candidaemia distribution was 86 
plotted in bar charts according to the observed species percentages in the studies. Candida 87 
parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis were grouped as 88 
Candida parapsilosis complex.42 In addition, Candida glabrata sensu stricto, Candida 89 
nivariensis and Candida bracarensis were summarized as C. glabrata complex.43,44 90 
Extrapolation 91 
We extrapolated daily candidaemia incidence and mortality rates in Europe using the number 92 
of UN European region inhabitants (740,813,959)45 and the population-based pooled 93 
incidence rate and mixed group based pooled D30 mortality rate. 94 
  95 
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Results 96 
The search algorithms identified 3,209 articles. Of these, we rated 979 as potentially relevant. 97 
We retrieved corresponding articles if needed for detailed review and evaluation. 872 studies 98 
did not match our inclusion criteria after detailed review (Figure 1). In total, we included 107 99 
studies in our analysis.13-16,18-22,25,26,34,36,37,46-137 Fifty13-16,22,37,52,55-86,114-116,120,121,126,128,129,133,136 100 
of 107 studies13-16,18-22,25,26,34,36,37,46-108 were teaching hospital-based, 18 were population-101 
based,20-22,25,26,34,36,87-100,123 22 were ICU-based18,19,46-51,53,54,110-113,117,119,122,125,131,132,135,137 and 102 
17 reported data on the mixed group.34,36,93,101-109,118,124,127,130,134 Seven studies comprised data 103 
on multiple subcategories (e.g. population-based plus mixed group).22,34,36,52,93,94,106 Eighty-104 
one studies were hospital-based13-16,18-22,25,26,34,36,37,46-108,110-120,122,125-127,129-132,134-137 and 26 105 
were laboratory-based (Figures S3, S12 and S17).20,21,25,26,36,56,57,87-92,94-106 
97,100,102,105,109,121,123,124,128,133 Sixty-seven studies were retrospective13-15,18,20,22,26,49,51-55,57-60,62-107 
66,68,72,75,77-86,88,89,91-95,100,101,103-105,111-116,118-121,123,126-128,132,133,135-138 and 40 108 
prospective.16,19,21,25,34,36,37,46-48,50,56,61,67,69-71,73,74,76,87,90,96-99,102,106-110,117,122,124,125,129-131,134 109 
Twenty-eight studies had their study midpoint within the 1990-2000 110 
decade,22,48,49,53,69,72,77,79,80,82-86,97-100,105-108,112,113,122,124,126,133 54 between 2001 and 201013-16,18-111 
21,25,26,34,36,37,46,47,50,51,54,55,60,61,63-68,70,71,73-76,78,81,90,92,93,95,96,102-112 
104,110,111,116,117,121,125,128,130,131,134,136,137 and 25 between 2011 and now.52,56-59,62,87-113 
89,91,94,101,109,114,115,118-120,123,127,129,132,134,135,138 Fifty-five studies were conducted in 114 
Southern,13,14,16,19,34,36,47,48,51-54,56-58,60-66,68,69,71,73-77,79,80,83,84,86,98,101,102,111,114-122,128-131,135,136,138 27 115 
studies in Northern,20-22,25,26,70,72,78,81,82,87-91,93-97,99,100,104,107,123,126,137 20 in 116 
Western15,18,37,46,49,50,55,67,85,92,105,108,110,112,113,125,127,132-134 and four in Eastern Europe 117 
(Tables S1-S3). 59,103,109,124 One study comprised a pan-European survey.27 118 
The articles reported 43,799candidaemia episodes in a population of 1,885,271,885person-119 
years in population-based surveys. In hospital-based studies, teaching hospitals observed  120 
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9,092 candidaemias per 12,191,293 admissions, and the mixed group of teaching and general 121 
hospitals yielded 5,387 candidaemias per 13,782,442 admissions. In ICU-based surveys, 122 
1,756candidaemia episodes per 450,607admissions were reported. 123 
 124 
Population-based epidemiology of candidaemia in Europe 125 
Population-based surveys yielded an overall pooled incidence rate (IR) of candidaemia of 126 
3.88 per 100,000 inhabitants per year (95% CI 3.42–4.35) (Figure 2 and Table 1).20-127 
22,25,26,34,36,87-98,100,123 Reported incidence rates per 100,000 people varied from 1.0 in England 128 
and Wales (1990-1999)100 to 10.4 in Denmark (01/2004-12/2006).95 Pooled analysis indicated 129 
that studies with a study median between 2001-2010 had a higher incidence rate of 130 
candidaemia (4.67; 95% CI 4.12–5.21)20,21,25,26,34,36,90,92-96 compared to studies with a study 131 
median between 1990 and 2000 (2.18; 95% CI 1.25–3.12)22,97,98,100 and studies with a study 132 
median between 2011 and now (3.22; 95% CI 2.88–3.56) (Figure 2) (p-value for interaction 133 
<0.001).87-89,91,94,123 Studies from southern European countries had a higher incidence rate of 134 
candidaemia (5.29; 95% CI 2.79–7.78)34,36,98 compared to studies from northern (3.77; 135 
95% CI 3.19–4.34)20-22,25,26,94-97,100,123 and western European countries (2.5; 95% CI 2.46–136 
2.54) (Figure S1) (p-value for interaction <0.001).92 Retrospective studies on the incidence of 137 
candidaemia in population-based studies showed a pooled IR of 3.39 (95% CI 2.832–138 
3.95)20,26,88,89,91-95,100,123 compared to prospective studies with 4.64 (95% CI 3.61–5.67) 139 
(Figure S2) (p-value for interaction <0.001).21,22,25,34,36,87,90,96-98 The degree of heterogeneity 140 
between population-based studies was high with I2= 99.8% (p <0·0001).. In population-based 141 
studies, C. albicans was the most prevalent cause of candidaemia, followed by C. glabrata 142 
complex and C. parapsilosis complex (Figure 7).20-22,25,26,34,36,87-98,100,123 Recent studies 143 
reported a trend to a higher share of Non-albicans Candida species compared to older studies 144 
over time (Figure 7).  145 
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Hospital-based incidence of candidaemia in Europe 146 
For the total hospital-based study setting without studies solely reporting ICU data, the 147 
estimated overall pooled incidence rate of candidaemia was 0.83 per 1,000 admissions per 148 
year (95% CI 0.72–0.94) (Figure S8 and Table 1). Reported incidence rates per 1,000 149 
admissions varied from 0.17 in Finland (01/1995-12/1999)22 to 2.19 in Portugal (01/2004-150 
12/2006).73 151 
In studies only reporting teaching hospital data, the pooled IR of candidaemia was 0.96 per 152 
1,000 admissions per year (95% CI 0.79–1.12) (Figure 3) 13-16,22,52,55-63,66,71,73-75,77,79,81,83-153 
85,114,115,120,136. Pooled analysis indicated that studies with a study median between 2001 and 154 
2010 had a higher IR with 1.11 (95% CI 0.83–1.39)13-16,55,60,61,63,66,71,73-75,81,136 compared to 155 
studies with a study median between 1990 and 2000 with 0.62 (95% CI 0.41–0.83),22,77,79,82-85 156 
and studies with a study median between 2011 and now with 0.97 (95% CI 0.56–1.39) 157 
(Figure 3) (p-value for interaction <0.001).52,56-59,62,114,115,120 Studies from southern European 158 
countries had a higher pooled IR (1.13, 95% CI 0.9–1.35)13,14,16,52,56-58,60-63,66,71,73-159 
75,77,79,83,84,114,115,120,136 compared to studies from northern (0.31; 95% CI 0.16–0.45),22,81,82 and 160 
western European countries (0.47; 95% CI 0.35–0.59).15,55,85 A single study from an eastern 161 
European country showed an IR of 0.25 (95% CI 0.05–0.91) (Figure S4) (p-value for 162 
interaction <0.001).59 Retrospective studies on the incidence of candidaemia in teaching 163 
hospitals showed a pooled IR of candidaemia of 0.9 (95% CI 0.71–1.09)13-15,22,52,55,57-164 
60,62,63,66,75,77,79,81-85,114,115,120,136 compared to prospective studies with 1.23 (95% CI 0.54–1.92) 165 
(Figure S5) (p-value for interaction <0.001).16,56,61,71,73,74 The degree of heterogeneity between 166 
teaching hospital-based studies was high with I2= 99.4%, p <0·0001. In teaching hospital-167 
based studies, C. albicans was the most prevalent cause of candidaemia followed by C. 168 
parapsilosis complex and C. glabrata complex (Figure S18)13-16,20-22,25,26,34,36,37,52,55-64,66-169 
98,100,105,114,115,120,136,138  170 
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For the mixed group (studies reporting on teaching plus general hospitals) without studies 171 
solely reporting ICU data, the overall pooled IR of candidaemia was 0.52 per 1,000 172 
admissions per year (95% CI 0.38–0.65) (Figure 4 and Table 1).34,36,93,102,105-109,127,130,134 173 
Studies with a study median between 2001 and 2010 had a higher pooled IR with 0.75 174 
(95% CI 0.42–1.07)34,36,93,102,130 compared to studies with a study median between 1990 and 175 
2000 with 0.30 (95% CI 0.28–0.32)105-108 or 2011 and now with 0.52 (95% CI 0.21–176 
0.83)109,127,134 (p-value for interaction <0.001) (Figure 4).105-108 Southern European countries 177 
had a higher pooled IR with 0.78 (95% CI 0.56–1.01)34,36,102,106,130 compared to studies from 178 
northern (0.29; 95% CI 0.23–0.35)93,106,107 and western European countries (0.3; 179 
95% CI 0.23–0.37).(Figure S6) (p-value for interaction <0.001).105,106,108,127,134 Retrospective 180 
studies on the incidence of candidaemia in the mixed group showed a pooled IR of 181 
candidaemia of 0.24 (95% CI 0.19–0.28)93,105,127 compared to prospective studies with 0.61 182 
(95% CI 0.44–0.78) (Figure S7).34,36,102,106-109,130,134 The degree of heterogeneity between 183 
mixed group-based studies was high with I2= 98.8%, p value for heterogeneity<0·0001. In the 184 
mixed group hospital-based studies, C. albicans was the most prevalent cause of candidaemia, 185 
followed by C. parapsilosis complex and C. glabrata complex.17,34,36,93,101-109,127,130,134 186 
(Figure S19)  187 
In the ICU-only setting, the pooled IR of candidaemia was 5.5 per 1,000 admissions per year 188 
(95% CI 4.31–6.69) (I2= 97.0%, p <0·0001) (Figure 5).19,46,48,49,51-53,110,112,113,122,135. 189 
C. albicans was the most prevalent cause of candidaemia, followed by C. glabrata complex 190 
and C. tropicalis19,46-51,53,110,112,113,122,135 Recent studies reported higher shares of Non-albicans 191 
Candida species (Figure S20). 192 
  193 
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Mortality of candidaemia in Europe 194 
Concerning mortality analysis, we differentiated between D30 and crude mortality rates 195 
(Tables 2 and 3). For the total study the pooled D30 mortality rate (MR) was 0.37 196 
(95% CI 0.35–0.39) (Figure S9 and Table 2).15,16,19,20,22,26,34,36,37,56,58-62,67-72,76,78,80,81,85-87,93,99,101-197 
104,106,107,109,127,129,138,139 Reported D30 mortality rates varied from 0.25 to 0.51.56,59 Overall 198 
pooled crude MR was 0.46 (95% CI 0.42–0.49) (Figure S13 and Table 3).13,18,37,46-199 
51,54,55,64,73,74,82-84,92,98,110,112,113,116-119,122,131,135-137 Reported crude mortality rates varied from 200 
0.24 to 0.83.18,135 201 
Population-based studies reported a pooled D30 MR of 0.34 (95% CI 0.29–0.39)20,26,34,36,87,99, 202 
teaching hospital-based studies showed a pooled D30 MR of 0.38 (95% CI 0.35–203 
0.40)15,16,22,37,56,58-62,67-72,76,78,80,81,85,86,129,138,139, the mixed group yielded a pooled D30 MR of 204 
0.37 (95% CI 0.34–0.40),36,93,101-104,106,107,109,127 and one ICU study reported 0.46 205 
(95% CI 0.40–0.52) (Figure S9) (p-value for interaction <0.001).19 For subgroup analysis, we 206 
excluded studies solely reporting on ICU patients. Studies with a study median between 1990 207 
and 2000, accounted for a pooled D30 MR of 0.36 (95% CI 0.32–0.39).22,69,72,80,85,86,99,106,107 208 
Pooled analysis showed that studies with a study median between 2011 and now had a higher 209 
D30 MR with 0.4 (95% CI 0.36–0.44) (Figure 6)56,58,59,62,87,101,109,127,129,138 compared to studies 210 
with a study median between 2001 and 2010 (0.36; 95% CI 0.32–0.39) (p-value for 211 
interaction <0.001).15,16,20,26,34,36,37,60-62,67,68,70,71,76,78,81,93,102-104,139 Studies from eastern 212 
European countries had a higher pooled D30 MR with 0.42 (95% CI 0.33–0.52)59,103,109 213 
compared to studies from southern (0.37; 95% CI 0.34–0.40)16,34,36,56,58,60-214 
62,68,69,71,76,80,86,101,102,129,138,139, western (0.37; 95% CI 0.32–0.43)15,37,67,85,127 and northern 215 
European countries (0.35; 95% CI 0.32–0.39) (Figure S10) (p-value for interaction 216 
<0.001).20,22,26,70,72,78,81,87,93,99,104,107 Retrospective studies showed a pooled D30 MR of 0.39 217 
(95% CI 0.36–0.41)15,20,22,26,58-60,62,68,72,78,80,81,85,86,93,101-106,109,127,138,139 compared to prospective 218 
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studies with 0.35 (95% CI 0.32–0.38) (Figure S11) (p-value for interaction 219 
<0.001).16,34,36,37,53,56,61,67,69-71,76,87,99,102,129,140 For studies regarding D30 MR the degree of 220 
heterogeneity was high with I2= 85.39%, p value for heterogeneity<0·001. 221 
Population-based studies reported a pooled crude MR of 0.40 (95% CI 039–0.41),92,98 222 
teaching hospital-based studies showed a pooled crude MR of 0.43 (95% CI 0.39–223 
0.47),13,55,64,73,74,82-84,122 and the ICU-only studies reported 0.49 (95% CI 0.43–0.55) 224 
(Figure S13 and Table 3) (p-value for interaction <0.001).18,37,46-51,54,110,112,113,117,119,122,131,135,137 225 
For subgroup analysis, we excluded studies solely reporting on ICU patients. The pooled 226 
crude MR among studies indicated that studies with a study median between 2001 and 2010 227 
had a higher crude MR with 0.43 (95% CI 0.39–0.47)13,55,64,73,74,92,116,136 compared to studies 228 
with a study median between 1990 and 2000 with 0.41 (95% CI 0.37–0.45) (Figure S14) (p-229 
value for interaction <0.001).82-84,98 The pooled crude MR among studies indicated that 230 
studies from southern European countries had a higher crude MR with 0.44 (95% CI 0.41–231 
0.47)13,64,73,74,83,84,98,116,136 compared to studies from western (0.40; 95% CI 0.39–0.41)55,92 and 232 
northern European countries (0.35; 95% CI 0.27–0.44) (Figure S15) (p-value for interaction 233 
<0.001).82 234 
Retrospective studies showed a pooled crude MR of 0.41 (95% CI 0.38–0.44)13,55,64,82-235 
84,92,116,118,136 compared to prospective studies with 0.46 (95% CI 0.37–0.55) . 73,74,98 For crude 236 
relative risk of death the degree of heterogeneity was high with I2= 67.88%, p value for 237 
heterogeneity<0.001. 73,74,98 73,74,98 72,73,97 70,71,95 70,71,95 70,71,95 70,71,95238 
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Comparative statistical analysis and meta-regression 239 
Patients in teaching hospitals were at a higher risk of contracting candidaemia compared to 240 
patients from the mixed group (pooled IR 0.96; 95% CI 0.79–1.12 (Figure 3) vs. 0.52; 241 
95% CI 0.38–0.65 (Figure 4 and Table 1). Candidaemia yields a slightly higher pooled D30 242 
MR in teaching hospitals alone in comparison to the mixed group of teaching and general 243 
hospitals (pooled MR 0.38; 95% CI 0.35–0.40 vs. 0.37; 95% CI 0.34–0.40) (Figure S9 and 244 
Table 2). Patients on ICUs showed higher pooled D30 MR with 0.46 compared to the mixed 245 
group of general and teaching hospitals (pooled MR 0.37; 95% CI 0.34–0.40) and teaching 246 
hospitals (pooled MR 0.38; 95% CI 0.35–0. 40) (Figure S9 and Table 2). To assess 247 
geographical differences by comparative statistical analysis, we regrouped studies according 248 
to geographical region. Studies solely reporting on ICU-based studies were excluded. The 249 
pooled incidence rate of candidaemia in Southern Europe was significantly higher than in 250 
Western and Northern Europe (Figures S1, S4, S6 and Table 1). Over time, there was 251 
significant increase of candidaemia incidence with a slight decrease during the current decade 252 
(Figures 2, 3, 4 and Table 1). Pooled D30 and crude mortality rates were highest in eastern 253 
and southern regions (Figures S10, S15 and Tables 2 and 3). Over time, there was an increase 254 
of pooled D30 and crude MR (Figures 6, S14, Tables 2 and 3). Further information regarding 255 
incidence rates and mortality rates with respect to scenario (retrospective vs. prospective) and 256 
type of study (hospital-based vs. laboratory based – Figures S12 and S17) are shown in the 257 
Supplement. 258 
Applied to an overall UN-European region population of 740,813,95945, a daily incidence rate 259 
of 79 Candida BSI (95% CI 69-88) can be extrapolated as a rough estimate for the UN-260 
European region (28,744 per year (95% CI 25,336 - 32,225)). Given the pooled D30 MR 261 
observed in the mixed group of this meta-analysis, we estimate 29 patients (95% CI 27–31) 262 
die in Europe from candidaemia every day. The uni-and multivariable meta-regression 263 
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analysis did not reveal any significant interaction between the IR of candidaemia and 264 
geographical origin, study period, scenario, and type of hospital. Similar findings were 265 
elucidated for crude and D30 MR of candidemia (Table S6). The variation explained by the 266 
covariates geographical origin, study period, scenario, and type of hospital ranged from 267 
38.59%, for IR in population based studies, up to 85.50% for crude MR. A meta-regression 268 
model for the crude MR and hospital-based IR was not applicable due to the low number of 269 
studies and lack of information. 270 
Publication bias by Egger`s test was examined and detected potential bias in ICU-based 271 
(Egger`s test p<0.002) and population-based studies (Egger`s test <0.001). We did not detect 272 
any evidence for publication bias among studies reporting crude or D30 MR (Egger’s test: 273 
p=0.228 and p=0.966). 274 
 275 
Discussion 276 
Candidaemia epidemiology in Europe currently relies on individual efforts of engaged 277 
researchers in the field of clinical mycology and microbiology. Our meta-analysis summarizes 278 
the available evidence on the incidence rate and mortality rate of candidaemia. We identified 279 
considerable differences between the observed clinical groups, European regions, as well as 280 
over time.  281 
Incidence and mortality rates of candidaemia were higher in teaching hospitals than in the 282 
mixed group. Some reasons for this observation may be more severe underlying diseases, 283 
more complex surgical procedures and higher numbers of intensive care beds in teaching 284 
hospitals.141,142 As expected, the highest incidence and mortality rates were found in the ICU 285 
setting.140 Intensive care patients harbour many of the well-established risk factors for 286 
candidaemia34,141-144 and are at higher risk for adverse outcomes. 287 
16 
 
In our analysis, we observed an increasing incidence of candidaemia over time, which is 288 
supported by other surveillance studies.25,97 A common explanation for this finding is the 289 
rising number of patients at risk for invasive candidiasis,142,145 as the number of elderly 290 
patients20,26,95,97 with complex and severe underlying conditions increases in European health 291 
care systems.68 Other causes that have been proposed are increased survival rates of pre-term 292 
neonates and of critical care patients, expanding indications for antineoplastic and 293 
immunosuppressive therapies, increased numbers of surgical procedures, solid organ and 294 
hematopoietic stem cell transplantations and implantation of indwelling devices, as well as 295 
use of parenteral nutrition and broad-spectrum antibiotics.140,142,146,147 296 
Our meta-analysis shows that mortality increases over time. It is possible that the increasing 297 
case severity and the associated worse outcomes counterbalanced advances in antifungal 298 
therapy. 299 
We found a higher incidence for candidaemia in Southern Europe in comparison to Northern 300 
or Western Europe throughout the groups. Numerous reasons may be considered for this 301 
observation: differences in climate, antibiotic prescription policy, candidaemia management, 302 
demographic development and setting of local health care systems may have significant 303 
impact on candidaemia incidence. To uncover the reasons for this difference, a comparative 304 
prospective study on individual risk factors is needed. 305 
The increasing rate of infections by NAC species represents a potentially hazardous 306 
development. Similar developments have been reported for the Americas and in various parts 307 
of the world by international authors.148-150 Increasing use of azoles, the standard antifungal 308 
drug of choice for Candida infections in many countries, lead to marked pressure on local 309 
epidemiology with elevated yields of NAC species. Intensity of the shifts varied throughout 310 
the observed groups and stresses the need for species identification and susceptibility testing 311 
after microbiological diagnosis and the obligation to consider local epidemiology. Especially 312 
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the increasing share of C. parapsilosis complex is of concern, as it may provide a challenge 313 
for current antifungal treatment strategies.1,8,51,151 Virulence and pathogenicity of some NAC 314 
species result in significant morbidity and mortality leading to increasing health care 315 
associated costs by prolonged hospital stays in nosocomial NAC candidaemia; this is 316 
especially of relevance in the growing group of immunocompromised patients. Recent studies 317 
report worrisome trends concerning Candida auris outbreaks.28,29 In the studies included in 318 
our analysis no identification of Candida auris was reported, such that cases could be 319 
misclassified in the group of unidentified, declared as other or Candida spp., or non-specified 320 
Candida due to potential misidentification by conventional biochemical testing.152 321 
Our meta-analysis has some inherent limitations. The included studies showed marked 322 
heterogeneity. We identified potential publication bias in population- and hospital based 323 
studies reporting incidence of candidaemia, which needs to be considered when interpreting 324 
the pooled results. In addition, bias could develop due to unrecognized confounders as all of 325 
the included studies were observational studies.153,154 Observed differences in local and 326 
national epidemiology may be confounded by the type of underlying study. These issues raise 327 
the question how to read a pooled IR of our meta-analyses. Still, meta-analysis is the only 328 
option to determine the overall population burden of candidaemia based on the available data 329 
and to investigate key determinants of individual risk by site and geographic region. Meta-330 
regression analysis was used to control for some potential confounders. 331 
Another limitation was the need to exclude a majority of articles due to insufficient reporting 332 
(Figure 1). We could not identify sources of heterogeneity in the meta-regression model, 333 
illustrating the pressing need to identify risk factors associated with IR and MR of 334 
candidaemia in future studies. Due to the varying length of study periods, we had to allocate 335 
studies by study median, with the possibility of allocating studies to distinctive decades with 336 
overlapping time periods, so that our classification is just the best possible approximation. It 337 
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must be considered that studies are published after conclusion of the observation period and 338 
sometimes after considerable delay, inevitably leading to a dwindling number of reports in the 339 
final study period. We still believed it is better to incorporate all available evidence instead of 340 
censoring the past years for the sake of homogeneity. Measurement biases may affect our 341 
presented results. Minor deviations in practice regarding pre-analytical (e.g. choice of culture 342 
system, blood draw volume, number and frequency of blood cultures, blood draw technique, 343 
and transport) and analytical (e.g. laboratory processing, culture duration, detection method, 344 
or identification method) procedures all have impact on the rate of detection, thus the 345 
measured incidence rate. As it is impossible to control for all such confounders and to balance 346 
each potential confounder against the others, the risk of bias should be considered high for all 347 
included studies. In addition, specific medical treatment standards and facilities are likely to 348 
influence epidemiology of candidaemia, but was not sufficiently reported. The reviewed 349 
publications did not always differentiate between unique patients or candidaemia episodes. 350 
Regarding species identification, we could not distinguish between studies with molecular 351 
from those with conventional identification, which has to be taken into consideration 352 
analysing rare and emerging Candida species. 353 
In summary, many excellent studies on candidaemia have been published across Europe, 354 
allowing some conclusions on the varying epidemiology in different hospital settings and 355 
geographic regions. However, a pan-European effort is clearly missing. It is needed to close 356 
gaps in our understanding of the epidemiology of candidaemia and to monitor trends in 357 
antifungal resistance and species shifts.  358 
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179 non-European
128 non-candidaemia
120 paediatric cohort 
6 studies due to duplicate 
data
2 study not retrievable
1 retracted by author 
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 857 
Figure 1: Study selection.858 
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 859 
 860 
Figure 2: Forest plot of the incidence of candidaemia for population-based studies by 861 
decade. 862 
Studies are identified by the name of the first author and year of publication. Sorted 863 
alphabetically. Total=admissions. Events=candidaemia cases. IR=incidence rate. 864 
CI=confidence interval. Weights are from random-effect analysis. Size of squares are 865 
analogous to the study’s weight. Diamonds represent the pooled incidence rates.  866 
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 867 
 868 
 869 
 870 
Figure 3: Forest plot of the incidence of candidaemia for studies on teaching hospitals by 871 
decade. 872 
Studies are identified by the name of the first author and year of publication. Sorted 873 
alphabetically. Studies reporting solely on ICU are excluded. Total=admissions. 874 
Events=candidaemia cases. IR=incidence rate. CI=confidence interval. Weights are from 875 
random-effect analysis. Size of squares are analogous to the study’s weight. Diamonds 876 
represent the pooled incidence rates.  877 
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 878 
 879 
Figure 4: Forest plot of the incidence of candidaemia for studies in the mixed group 880 
(general and teaching hospitals) by decade. 881 
Studies are identified by the name of the first author and year of publication. Sorted 882 
alphabetically. Studies reporting solely on ICU are excluded. Total=admissions. 883 
Events=candidaemia cases. IR=incidence rate. CI=confidence interval. Weights are from 884 
random-effect analysis. Size of squares are analogous to the study’s weight. Diamonds 885 
represent the pooled incidence rates.  886 
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 887 
 888 
 889 
Figure 5: Forest plot of the incidence of candidaemia for ICU-based studies. 890 
Studies are identified by the name of the first author and year of publication. Sorted 891 
alphabetically. Total=admissions. Events=candidaemia cases. IR=incidence rate. 892 
CI=confidence interval. Weights are from random-effect analysis. Size of squares are 893 
analogous to the study’s weight. Diamonds represent the pooled incidence rates.  894 
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 895 
  896 
 897 
 898 
Figure 6: Forest plot of the day 30 mortality of candidaemia by decade. 899 
Studies are identified by the name of the first author and year of publication. Sorted 900 
alphabetically. Studies reporting solely on ICU are excluded. Total=cases. Events=deaths. 901 
ES=effect estimates. CI=confidence interval. Weights are from random-effect analysis. Size 902 
of squares are analogous to the study’s weight. TH=teaching hospital subgroup of total study 903 
population. Diamonds represent the pooled D30 mortality rates. *=reported Day 20 mortality.904 
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Figure 7: Candida species differentiation by population-based studies.  907 
Studies are identified by the name of the first author, the journal and year of publication. Sorted by chronologically by median of study period from left to right. 908 
*=C. ciferrii, C. dubliniensis, C. famata, C. guilliermondii, C. humicola, C. inconspicua, C. kefyr, C. lipolytica, C. lusitaniae, C. norvegensis, C. pelliculosa, C. 909 
rugusa, C. sake, C. utilis, unidentified, declared as other or Candida spp., or non-specified Candida.910 
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Table 1. Incidence rate stratified by different explanatory variables 911 
  Studies 
(N) 
ES Incidence Rate 
(95% CI) 
p-value for subgroup interaction 
Population-based 
 Overall 
  
25 
 
3.88 (3.42, 4.35) 
 
 
   Decade    p<0.001 
 1990-2000 4 2.18 (1.25, 3.12)  
 2001-2010 14 4.67 (4.12, 5.21)  
 2011-Now 7 3.22 (2.88, 3.56)  
   Region    p<0.001 
 Northern 21 3.77 (3.19, 4.34)  
 Southern 3 5.29 (2.79, 7.78)  
 Eastern - -  
 Western 1 2.50 (2.46, 2.54)  
   Scenario    p<0.001 
 Retrospective 15 3.39 (2.83, 3.95)  
 Prospective 10 4.64 (3.61, 5.67)  
   Type    p<0.001 
 Hospital-based 4 4.62 (2.57, 6.66)  
 Laboratory-based 21 3.74 (3.25, 4.24)  
Hospital-based 
 Overall 
 
 
 
45 
 
0.83 (0.72, 0.94) 
 
 
   Scenario    p <0.001 
 Retrospective 28 0.83 (0.68, 0.98)  
 Prospective 17 0.82 (0.66, 0.98)  
Teaching Hospital 
 Overall 
  
31 
 
0.96 (0.79, 1.12) 
 
 
   Decade    p<0.001 
 1990-2000 7 0.62 (0.41, 0.83)  
 2001-2010 15 1.11 (0.83, 1.39)  
 2011-Now 9 0.97 (0.56, 1.39)  
   Region    p<0.001 
 Northern 3 0.31 (0.16, 0.45)  
 Southern 24 1.13 (0.90, 1.35)  
 Eastern 1 0.25 (0.05, 0.918)  
 Western 3 0.47 (0.35, 0.59)  
   Scenario    p<0.001 
 Retrospective 25 0.90 (0.71, 1.09)  
 Prospective 6 1.23 (0.54, 1.92)  
Mixed Group 
 Overall 
 
 
 
14 
 
0.52 (0.38, 0.65) 
 
 
   Decade    p<0.001 
  1990-2000 6 0.30 (0.28, 0.32)  
 2001-2010 5 0.75 (0.42, 1.07)  
 2011-Now 3 0.52 (0.21, 0.83)  
   Region    p<0.001 
 Northern 3 0.29 (0.23, 0.35)  
 Southern 5 0.78 (0.56 1.01)  
 Eastern 1 3.97 (2.87, 5.34)  
 Western 5 0.30 (0.23, 0.37)  
   Scenario    p<0.001 
 Retrospective 3 0.24(0.19, 0.28)  
 Prospective 11 0.61 (0.44, 0.78)  
ICU 
 Overall 
  
12 
 
5.50 (4.31, 6.69) 
 
 
 912 
N=number. ES=estimate. CI=confidence interval. Weights are from random-effect analysis. 913 
  914 
40 
 
Table 2. Day 30 mortality of candidaemia stratified by different explanatory variables 915 
 916 
 Studies 
(N) 
ES D30 Mortality 
(95% CI) 
p-value for subgroup 
interaction 
Setting 
 Overall 
 
41 
 
0.38 (0.36, 0.40) 
p < 0.001 
 
   Population-based 6 0.34 (0.29, 0.39)  
   Teaching-Hospital 25 0.38 (0.35, 0.40)  
   Mixed Group 9 0.37 (0.34, 0.40)  
   ICU 1 0.37 (0.35, 0.39)  
Decade* 
 Overall 
 
40 
 
0.37 (0.35, 0.39) 
p < 0.001 
 
   1990-2000 9 0.36 (0.32, 0.39)  
   2001-2010 21 0.36 (0.34, 0.39)  
   2011-Now 10 0.40 (0.36, 0.44)  
Region* 
 Overall 
 
40 
 
0.37 (0.35, 0.39) 
p < 0.001 
 
   Northern 12 0.35 (0.32, 0.39)  
   Southern 19 0.37 (0.34, 0.40)  
   Eastern 3 0.42 (0.33, 0.52)  
   Western 5 0.37 (0.32, 0.43)  
   Europe 1 0.38 (0.36, 0.40)  
Scenario* 
 Overall 
 
40 
 
0.37 (0.35, 0.39) 
p < 0.001 
 
   Retrospective 23 0.39 (0.36, 0.41)  
   Prospective 17 0.35 (0.32, 0.38)  
Type* 
 Overall 
 
40 
 
0.37 (0.35, 0.39) 
p < 0.001 
 
   Hospital-based 33 0.38 (0.36, 0.40)  
   Laboratory-based 7 0.33 (0.30, 0.35)  
 917 
N=number.ES=Estimate. D30=Day 30. CI=confidence interval. Weights are from random-918 
effect analysis. *=Studies reporting solely on ICU are excluded. 919 
 920 
 921 
  922 
41 
 
Table 3. Crude mortality of candidaemia stratified by different explanatory variables 923 
 924 
 Studies 
(N) 
ES Crude Mortality 
(95% CI) 
p-value for subgroup 
interaction 
Setting 
 Overall 
 
31 
 
0.46 (0.42, 0.49) 
p < 0.001 
 
   Population-based 2 0.40 (0.39, 0.41)  
   Hospital-based 11 0.43 (0.39, 0.47)  
   ICU 18 0.49 (0.43, 0.55)  
Decade* 
 Overall 
 
13 
 
0.42 (0.39, 0.45) 
p < 0.001 
 
   1990-2000 4 0.41 (0.37, 0.45)  
   2001-2010 8 0.43 (0.39, 0.47)  
   2011-Now 1 0.40 (35-0.46)  
Region* 
 Overall 
 
13 
 
0.42 (0.39, 0.45) 
p < 0.001 
 
   Northern 1 0.35 (0.27, 0.44)  
   Southern 10 0.44 (0.41, 0.47)  
   Eastern - -  
   Western 2 0.40 (0.39, 0.41)  
Scenario* 
 Overall 
 
13 
 
0.42 (0.39, 0.45) 
p < 0.001 
 
   Retrospective 10 0.41 (0.38, 0.44)  
   Prospective 3 0.46 (0.37, 0.55)  
Type* 
 Overall 
 
13 
 
0.42 (0.39, 0.45) 
p < 0.001 
 
   Hospital-based 12 0.42 (0.39, 0.46)  
   Laboratory-based 1 0.40 (0.39, 0.41)  
 925 
N=number.ES=Estimate. D30=Day 30. CI=confidence interval. Weights are from random-926 
effect analysis. *=Studies reporting solely on ICU are excluded. 927 
